Inventory increased 127.5%
Inventory changed +127.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Inventory changed +127.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +63.0% from the comparable as-filed period.
Working capital changed +17.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed +1549 basis points from the comparable as-filed period.
Working capital / assets changed +192 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
SBC / revenue changed -538 basis points from the comparable as-filed period.
Cash & equivalents changed -28.6% from the comparable as-filed period.
Inventory / revenue changed +3575 basis points from the comparable as-filed period.
Revenue changed +13.2% from the comparable as-filed period.
Research & development changed -15.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
R&D / revenue changed -1576 basis points from the comparable as-filed period.
Receivables / revenue changed -1029 basis points from the comparable as-filed period.
Gross margin changed -115 basis points from the comparable as-filed period.
Trade receivables changed -12.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Current assets changed +14.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Total assets changed +10.4% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Current liabilities changed +9.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Gross profit changed +11.0% from the comparable as-filed period.
Shares outstanding changed +3.4% from the comparable as-filed period. The change ranks at the 25th percentile of 8 prior comparable changes.
Stock-based compensation changed -9.9% from the comparable as-filed period.
Current ratio changed +4.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Selling, general & administrative changed +8.1% from the comparable as-filed period.
Free-cash-flow proxy changed -389.0% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash flow changed -273.1% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 3 consecutive comparable moves in the opposite direction.
Operating margin changed +1077 basis points from the comparable as-filed period.
Operating income changed +24.9% from the comparable as-filed period.
Net income changed +25.6% from the comparable as-filed period.
Inventory changed +104.5% from the comparable as-filed period.
SBC / revenue changed -861 basis points from the comparable as-filed period.
Revenue changed +16.9% from the comparable as-filed period.
Inventory / revenue changed +3432 basis points from the comparable as-filed period.
Gross margin changed -163 basis points from the comparable as-filed period.
Cash & equivalents changed -19.0% from the comparable as-filed period.
Gross profit changed +13.7% from the comparable as-filed period.
Stock-based compensation changed -16.2% from the comparable as-filed period.
Capex / revenue changed -137 basis points from the comparable as-filed period.
Research & development changed -1.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Selling, general & administrative changed +6.9% from the comparable as-filed period.
Capital expenditure changed -13.3% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.